Genomic Health announced the availability of Oncotype DX prostate cancer test, the first-of-its-kind multi-gene test, following a presentation at the 2013 American Urological Association (AUA) Annual Meeting. The test measures the level of expression of 17 genes across four biological pathways to predict prostate cancer aggressiveness. Results are reported as a Genomic Prostate Score (GPS) that ranges from 0–100 and is combined with other clinical factors to further define a patient’s risk prior to treatment intervention.
Oncotype DX prostate cancer test was shown to strongly predict disease aggressiveness (P=0.002), offering additional information beyond the PSA and biopsy Gleason score. This novel biopsy-based test has been validated to guide treatment decisions using the prostate needle biopsy sample taken before the prostate is removed, thus allowing the opportunity for low-risk patients to avoid invasive treatments such as radical prostatectomy or radiation.
Six feasibility and development studies were conducted to evaluate >700 patients. In the UCSF validation study (N=395), additional information from the GPS score significantly increased the number of patients identified as having very low risk, and thus appropriate for active surveillance (from 5–10% to 26%). Similarly, about 10% of patients originally classified as very low or low risk were identified by GPS as having more aggressive disease.
For more information call (866) 662-6897 or visit the Oncotype DX website.